Literature DB >> 22228316

Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications.

Matthieu P K Crews1, Oliver D Howes.   

Abstract

OBJECTIVE: Osteoporosis is increasingly common worldwide and there is a growing concern that the long-term use of antipsychotic medications increases the risk of this disorder. In this review, we consider whether antipsychotics may contribute to the development of osteoporosis through reductions in bone mineral density, discuss the possible mechanisms involved and consider the clinical implications of such a relationship.
METHODS: We searched the literature for studies in this area published between 1966 and 2010 using the Medline and PubMed databases, supplemented by hand searches of retrieved reports.
RESULTS: The available data indicate that statistically significant reductions in bone mineral density are frequently seen in patients prescribed with antipsychotic medications and suggest that there is a higher incidence of clinically significant reductions compared with the normal population.
CONCLUSIONS: Clinicians should be aware for the potential negative effects of antipsychotic medications on bone mineral density, particularly in patients with additional risk factors for osteoporosis. Recommendations regarding routine monitoring of bone mineral density for patients prescribed antipsychotic medications cannot be made on the basis of existing evidence, and more research is required.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228316      PMCID: PMC3731625          DOI: 10.1002/hup.1265

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  37 in total

1.  Alendronic acid for antipsychotic-related osteopenia.

Authors:  Oliver Howes; Shubulade Smith
Journal:  Am J Psychiatry       Date:  2004-04       Impact factor: 18.112

Review 2.  Examining the developing bone: What do we measure and how do we do it?

Authors:  M A Petit; T J Beck; S A Kontulainen
Journal:  J Musculoskelet Neuronal Interact       Date:  2005 Jul-Sep       Impact factor: 2.041

Review 3.  Diagnosis and epidemiology of osteoporosis.

Authors:  Elaine Dennison; Zoe Cole; Cyrus Cooper
Journal:  Curr Opin Rheumatol       Date:  2005-07       Impact factor: 5.006

4.  Prevalence and magnitude of osteopenia in patients with prolactinoma.

Authors:  M J Kayath; A M Lengyel; J G Vieira
Journal:  Braz J Med Biol Res       Date:  1993-09       Impact factor: 2.590

5.  The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats.

Authors:  Takeshi Kunimatsu; Juki Kimura; Hitoshi Funabashi; Tadashi Inoue; Takaki Seki
Journal:  Regul Toxicol Pharmacol       Date:  2010-08-13       Impact factor: 3.271

6.  Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.

Authors:  Daniel Becker; Olga Liver; Roberto Mester; Micha Rapoport; Abraham Weizman; Mordechai Weiss
Journal:  J Clin Psychiatry       Date:  2003-07       Impact factor: 4.384

7.  Estrogen in severe mental illness: a potential new treatment approach.

Authors:  Jayashri Kulkarni; Anthony de Castella; Paul B Fitzgerald; Caroline T Gurvich; Michael Bailey; Cali Bartholomeusz; Henry Burger
Journal:  Arch Gen Psychiatry       Date:  2008-08

8.  Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.

Authors:  Taishiro Kishimoto; Koichiro Watanabe; Naoki Shimada; Kazuya Makita; Gohei Yagi; Haruo Kashima
Journal:  J Clin Psychiatry       Date:  2008-03       Impact factor: 4.384

9.  Decreased bone mineral density in medicated psychiatric patients.

Authors:  U Halbreich; N Rojansky; S Palter; M Hreshchyshyn; J Kreeger; Y Bakhai; R Rosan
Journal:  Psychosom Med       Date:  1995 Sep-Oct       Impact factor: 4.312

10.  Bone density in amenorrheic women with and without hyperprolactinemia.

Authors:  J A Schlechte; B Sherman; R Martin
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

View more
  17 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Evaluation of health promotion programmes in severe mental illness: theory and practice.

Authors:  Fenneke M van Hasselt; Paul F M Krabbe; Maarten J Postma; Anton J M Loonen
Journal:  Int J Methods Psychiatr Res       Date:  2014-12-09       Impact factor: 4.035

Review 3.  Hyperprolactinemia and bone.

Authors:  Luigi di Filippo; Mauro Doga; Eugenia Resmini; Andrea Giustina
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

4.  Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice.

Authors:  Xingsheng Li; Tim R Nagy
Journal:  Int J Body Compos Res       Date:  2013-01-28

5.  Evaluation of serum prolactin levels in intellectually disabled patients using antipsychotic medications.

Authors:  Tammy L Lambert; Kevin C Farmer; Nancy C Brahm
Journal:  Int J Endocrinol Metab       Date:  2012-12-21

Review 6.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 7.  Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences.

Authors:  Chien-Yu Chen; Hsien-Yuan Lane; Chieh-Hsin Lin
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-08-31       Impact factor: 2.582

8.  Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study.

Authors:  Christine van der Leeuw; Sanne Peeters; Patrick Domen; Marinus van Kroonenburgh; Jim van Os; Machteld Marcelis
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

9.  Screening, assessment, and treatment of osteoporosis for the nurse practitioner: key questions and answers for clinical practice--a Canadian perspective.

Authors:  Peggy Rice; Upender Mehan; Celeste Hamilton; Sandra Kim
Journal:  J Am Assoc Nurse Pract       Date:  2014-06-09       Impact factor: 1.165

10.  Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case-Control Study in Australia.

Authors:  Michael J Leach; Nicole L Pratt; Elizabeth E Roughead
Journal:  Drugs Real World Outcomes       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.